Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse

NCT02330991 is registered in ClinicalTrials.gov with Beijing Sanbo Brain Hospital as lead sponsor.

NCT NCT02330991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02330991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse
Lead sponsor
Beijing Sanbo Brain Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
September 30, 2020
Enrollment
204 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma